X4 Pharmaceuticals Inc (XFOR)

Feb 19, 2025, 7:35 AM EST - 3 days ago

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

Feb 6, 2025, 7:35 AM EST - 16 days ago

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

Feb 3, 2025, 4:05 PM EST - 19 days ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 24, 2025, 7:36 AM EST - 4 weeks ago

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

Jan 13, 2025, 7:35 AM EST - 5 weeks ago

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

Nov 14, 2024, 8:00 AM EST - 3 months ago

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

Nov 13, 2024, 9:31 PM EST - 3 months ago

X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:07 AM EST - 3 months ago

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 6:01 AM EST - 3 months ago

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

Oct 24, 2024, 8:00 AM EDT - 4 months ago

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

Oct 1, 2024, 4:05 PM EDT - 5 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 28, 2024, 8:00 AM EDT - 6 months ago

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

Aug 10, 2024, 9:30 AM EDT - 7 months ago

X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 6:01 AM EDT - 7 months ago

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Jul 2, 2024, 6:17 PM EDT - 8 months ago

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

Jun 27, 2024, 6:30 AM EDT - 8 months ago

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

Jun 24, 2024, 4:51 AM EDT - 8 months ago

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

MRK NTLA ARWR VRNA

May 29, 2024, 4:30 PM EDT - 9 months ago

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

May 13, 2024, 8:00 AM EDT - 10 months ago

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 9, 2024, 6:30 AM EDT - 10 months ago

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

May 7, 2024, 6:01 AM EDT - 10 months ago

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

Apr 30, 2024, 8:00 AM EDT - 10 months ago

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

Apr 29, 2024, 5:02 PM EDT - 10 months ago

X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside

Apr 29, 2024, 6:37 AM EDT - 10 months ago

US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease

Apr 29, 2024, 6:30 AM EDT - 10 months ago

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

Apr 1, 2024, 8:00 AM EDT - 11 months ago

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

Mar 21, 2024, 11:35 AM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 12, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

Dec 13, 2023, 11:43 PM EST - 1 year ago

X4: Dip Following Mixed Results In Chronic Neutropenia Indication Worth Buying

Dec 9, 2023, 12:00 PM EST - 1 year ago

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

Nov 10, 2023, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences

Nov 9, 2023, 12:37 PM EST - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 6:01 AM EST - 1 year ago

X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates

Nov 2, 2023, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023

Oct 31, 2023, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome

Oct 18, 2023, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors

Sep 19, 2023, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Sep 6, 2023, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Sep 5, 2023, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome

Aug 24, 2023, 9:19 AM EDT - 1 year ago

X4: De-Risking By WHIM Indication, Promising Potential For Expansion To Larger Market

Aug 10, 2023, 12:38 PM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 6:05 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program

Aug 8, 2023, 4:05 PM EDT - 1 year ago

X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

Aug 3, 2023, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital

Aug 2, 2023, 8:01 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023

Jun 23, 2023, 12:32 PM EDT - 1 year ago

X4 Pharmaceuticals: Mavorixafor Could Change Chronic Neutropenic Treatment Landscape

Jun 13, 2023, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals Expected to Join Russell 3000® Index

May 16, 2023, 4:01 PM EDT - 1 year ago

X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

May 16, 2023, 8:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market